An observational study in Myeloma, sponsored by Odense University Hospital. Not yet recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Odense University Hospital · Observational
The main goal of the project is to characterize the bone marrow immunological milieu and investigate potential treatment defining events of the tumor microenvironment in relapsed and refractory multiple myeloma (RRMM) patients receiving BCMA-targeted therapies.
This is a non-interventional, multicenter study conducted in collaboration with the Nordic Myeloma Study Group (NMSG). The study comprises a translational element and a prospective observational cohort. The primary objective of the study is to characterize the bone marrow immunological milieu and genomic profile post BCMA-targeted therapy and before initiation of subsequent treatment.
2,314 studies on the registry are indexed under Neoplasms, Plasma Cell; 247 are open to participants now.
This study's planned enrollment of 50 is below the median of 150 across 266 observational studies indexed under Neoplasms, Plasma Cell.
Browse Neoplasms, Plasma Cell studies →Odense University Hospital is the lead sponsor of 477 studies on the registry; 109 are open to participants now.
Counted across the registry records on this site, refreshed daily.
To characterize the bone marrow immunological milieu and genomic profile post BCMA-targeted therapy and before initiation of subsequent treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Initiated subsequent anti-myeloma treatment before inclusion.
T-cell compartment fitness at the time of disease progression
Time frame: At the time of relapse: Bone marrow sampling will be performed within 4 weeks of relapse, as defined according to IMWG criteria, and prior to initiation of subsequent therapy.
Genetic status of the BCMA locus at relapse following BCMA-targeted therapy
Time frame: At the time of relapse: Bone marrow sampling will be performed within 4 weeks of relapse, as defined according to IMWG criteria, and prior to initiation of subsequent therapy.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 87 non-industry observational studies under Neoplasms, Plasma Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 95. This study's planned 23 months is below that.
Counting every sponsor, half of 114 studies reached it within 48 months; a quarter within 27 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.